These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7940937)

  • 41. Individualization of cyclosporine therapy in renal transplantation.
    Lee SF; Yang WC; Loong CC; King KL; Lin MF
    Transplant Proc; 1994 Aug; 26(4):1917-9. PubMed ID: 8066624
    [No Abstract]   [Full Text] [Related]  

  • 42. Biotransformation of cyclosporin G in comparison to cyclosporine.
    Mangold JB; Schran HF; Yatscoff RW; Weitzel WF; Leichtman AB
    Transplant Proc; 1994 Oct; 26(5):3013-6. PubMed ID: 7940950
    [No Abstract]   [Full Text] [Related]  

  • 43. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 44. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period.
    Amante AJ; Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2162-3. PubMed ID: 8769187
    [No Abstract]   [Full Text] [Related]  

  • 46. Cyclosporine pharmacology.
    Lee JI; Canafax DM
    Transplant Proc; 1996 Aug; 28(4):2156-8. PubMed ID: 8769185
    [No Abstract]   [Full Text] [Related]  

  • 47. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
    Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract]   [Full Text] [Related]  

  • 48. A randomized prospective study of the conversion from cyclosporine to microemulsion form cyclosporine in stable renal transplant patients.
    Jirasiritham S; Sumethkul V; Jirasiritham S
    Transplant Proc; 1998 Nov; 30(7):3524-5. PubMed ID: 9838544
    [No Abstract]   [Full Text] [Related]  

  • 49. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine.
    Mueller EA; Kovarik JM; Kutz K
    Transplant Proc; 1994 Oct; 26(5):2957-8. PubMed ID: 7940933
    [No Abstract]   [Full Text] [Related]  

  • 50. The effect of obesity on cyclosporine pharmacokinetics in uremic patients.
    Flechner SM; Kolbeinsson MC; Lum B; Tam J; Moran T
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1446-8. PubMed ID: 2652464
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of meal composition on cyclosporine absorption.
    Honcharik N; Yatscoff RW; Jeffery JR; Rush DN
    Transplantation; 1991 Dec; 52(6):1087-9. PubMed ID: 1750071
    [No Abstract]   [Full Text] [Related]  

  • 52. Engineering polysaccharide-based polymeric micelles to enhance permeability of cyclosporin A across Caco-2 cells.
    Francis MF; Cristea M; Yang Y; Winnik FM
    Pharm Res; 2005 Feb; 22(2):209-19. PubMed ID: 15783068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features.
    Friman S; Bäckman L
    Clin Pharmacokinet; 1996 Mar; 30(3):181-93. PubMed ID: 8882300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
    Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
    Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
    [No Abstract]   [Full Text] [Related]  

  • 56. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 57. Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral TM.
    Foradori AC; Martínez L; Elberg A; Vaccarezza A; Loveluck A; Pinto C
    Transplant Proc; 1995 Apr; 27(2):1813-4. PubMed ID: 7725515
    [No Abstract]   [Full Text] [Related]  

  • 58. Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
    Holt DW; Mueller EA; Kovarik JM; van Bree JB; Richard F; Kutz K
    Transplant Proc; 1995 Feb; 27(1):1434-7. PubMed ID: 7878935
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics of a new galenical formulation of oral cyclosporine A in stable kidney transplanted patients.
    Foradori AC; Martínez L; Vacarezza A; Elberg L; Loveluck A; Pinto C
    Transplant Proc; 1994 Oct; 26(5):2969-72. PubMed ID: 7940937
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.